`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`DR.REDDY’S LABORATORIES INC. and
` DR. REDDY’S LABORATORIES LTD.,
`Petitioners,
`
`v.
`
`MERCK SHARP & DOHME CORP.,
`Patent Owner.
`__________________
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`__________________
`
`PATENT OWNER’S PRELIMINARY RESPONSE
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`The Petition at issue is a “Me-Too” petition brought by Dr. Reddy’s
`
`Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. (collectively, “Petitioners” or
`
`“DRL”) after the Board instituted trial on the petition of Mylan Pharmaceuticals
`
`Inc. (“Mylan”) in IPR2020-00040 (“Mylan Proceeding”). Paper 2. DRL filed a
`
`motion for joinder within one month of institution of the Mylan Proceeding,
`
`seeking joinder. Paper 3. Merck has filed an opposition to the joinder motion,
`
`Paper 7, and has participated in two calls with the Board to address various
`
`conditions pertinent to joinder.
`
`Pursuant to 37 C.F.R. § 42.107(b), Patent Owner Merck Sharp & Dohme
`
`Corp. (“Merck”) hereby files a preliminary response in the above captioned case.
`
`I.
`
`If Joinder Is Ordered, Merck Reserves All Rights To Present Evidence
`and Argument In Response to the DRL Petition in Its Patent Owner
`Response and Other Papers.
`
`In the Mylan Proceeding, Merck filed a Preliminary Patent Owner Response
`
`opposing institution. IPR2020-00040, Paper 10. In that filing, Merck argued that
`
`the Board should exercise its discretion pursuant to §§ 325(d) and 314(a) to deny
`
`institution, and also argued that Mylan’s grounds were deficient because they did
`
`not address the stoichiometry required by all challenged claims. Id. The Board
`
`granted Mylan’s petition and instituted review in IPR2020-00040 notwithstanding
`
`Merck’s Preliminary Patent Owner Response.
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`For efficiency and to conserve judicial resources, Merck will not restate, in
`
`this Preliminary Patent Owner Response, all the arguments it made in the
`
`Preliminary Patent Owner Response in the Mylan Proceeding, which the Board has
`
`rejected, preliminarily or otherwise. Paper 21 at 64. However, Merck does not
`
`waive any such evidence or arguments and reserves all rights in the above
`
`captioned or any consolidated proceeding. Patent Owner specifically reserves all
`
`rights to submit a Patent Owner Response and/or a Motion to Amend pursuant to
`
`37 C.F.R. §§ 42.120 and 42.121. Patent Owner reserves the right to address
`
`grounds presented in the Petition should the Board institute inter partes review, to
`
`dispute in the Patent Owner’s Response any fact alleged to be material by
`
`Petitioners, and to provide material facts in support of Patent Owner’s position.
`
`Patent Owner reserves the right to raise any and all arguments against those
`
`grounds and in favor of patentability during the trial.
`
`II.
`
`If Joinder Is Not Ordered, the Board Should Exercise Its Discretion and
`Decline to Institute Trial Under § 314(a).
`
`In Merck’s Preliminary Patent Owner Response in the Mylan proceeding,
`
`Merck argued that discretionary denial of institution was warranted pursuant to §
`
`314(a) because trial on Mylan’s petition would be an inefficient use of the Board’s
`
`limited resources given that the same patent, arguments, and evidence were the
`
`subject of parallel proceedings in the district courts. IPR2020-00040, Paper 10 at
`
`23-30.
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`In its institution decision, the Board rejected these arguments in part because
`
`the Board expected “to issue a final written decision at least five months before the
`
`MDL trial date,” Id., Paper 21 at 28 (emphasis in original). The Board also
`
`declined to exercise its discretion because of the stage of the MDL proceedings at
`
`the time, noting that “a claim construction hearing is not scheduled until three
`
`months after the institution due date.” Id.
`
`Neither consideration remains true here. First, trial on the DRL petition
`
`could lag as much as six months behind the Mylan proceeding and a final written
`
`opinion may not be due until after trial in the MDL. See IPR2020-00040, EX 2006
`
`(MDL Scheduling Order). Second, claim construction briefing has already
`
`concluded in the MDL, and a claim construction hearing was held on August 18,
`
`2020. See EX2040 (MDL Docket). Fact discovery is proceeding this Fall and
`
`opening expert reports are due in January 2021.
`
`These circumstances distinguish the posture of the DRL petition from
`
`Mylan’s and warrant discretionary denial under § 314(a). See NHK Spring Co.,
`
`Ltd. v. Intri-Plex Techs., Inc., IPR2018-00752, Paper 8 at 20 (P.T.A.B. Sept. 12,
`
`2018) (precedential). Even DRL concedes that absent joinder, “a separate IPR
`
`proceeding involving DRL would needlessly duplicate efforts with multiple briefs,
`
`experts and hearings on the same patent claims and grounds already being
`
`litigated.” Paper 9 at 3. This kind of duplication and waste of resources is of the
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`exact kind § 314(a) was designed to prevent. See Patent Trial and Appeal Board
`
`Consolidated Trial Practice Guide (Nov. 2019) at 59 (“Based on the Board’s
`
`experience, one petition should be sufficient to challenge the claims of a patent in
`
`most situations. Two or more petitions filed against the same patent at or about the
`
`same time . . . may place a substantial and unnecessary burden on the Board and
`
`the patent owner and could raise fairness, timing, and efficiency concerns.”) Apart
`
`from the ongoing Mylan IPR regarding the same patent, Petitioners and Patent
`
`Owner, too, are already involved in ongoing litigation regarding the same patent
`
`and arguments in district court. See EX2039 (DRL Complaint).
`
`If the Board denies joinder, it should exercise its discretion and not institute
`
`an IPR on DRL’s Petition.
`
`
`
`Date: August 20, 2020
`
`
`
`
`
`Respectfully submitted,
`
`/Stanley E. Fisher/
`Stanley E. Fisher (Reg. No. 55,820)
`Bruce R. Genderson (Pro Hac Vice
`motion to be submitted)
`Jessamyn S. Berniker (Reg. No. 72,328)
`Alexander S. Zolan (Pro Hac Vice
`motion to be submitted)
`Elise M. Baumgarten (Pro Hac Vice
`motion to be submitted)
`Shaun P. Mahaffy (Reg. No. 75,534)
`Anthony H. Sheh (Reg. No. 70,576)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`T: (202) 434-5000
`F: (202) 434-5029
`sfisher@wc.com
`bgenderson@wc.com
`jberniker@wc.com
`azolan@wc.com
`ebaumgarten@wc.com
`smahaffy@wc.com
`asheh@wc.com
`
`
`Counsel for Patent Owner
`Merck Sharp & Dohme Corp.
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Case No. IPR2020-01060
`U.S. Patent No. 7,326,708
`
`
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on August 20, 2020, by delivering a
`
`copy via electronic mail on the following attorneys of record:
`
`Russell W. Faegenburg
`Tedd W. Van Buskirk
`Michael H. Teschner
`LERNER, DAVID, LITTENBERG,
`KRUMHOLZ & MENTLIK, LLP
`20 Commerce Drive, Cranford, New
`Jersey 07016
`(908) 518-6367
`Rfaegenburg.ipr@ldlkm.com
`Tvanbuskirk@lernerdavid.com
`litigation@lernerdavid.com
`MTeschner.ipr@ldlkm.com
`
`
`
`/Anthony H. Sheh/
`Anthony H. Sheh
`Reg. No. 70,576
`
`
`
`
`
`
`
`
`
`
`
`